$84.84
Value $1.1B
IRMD and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$84.84
Value $1.1B
$144.46
Value $357B
iRadimed (IRMD) has a market value of $1.1B and Merck & Company (MRK) $357B. Over the last year, with dividends, IRMD moved +2.0% and MRK +60.0%. The P/E is 45.2 for IRMD and 145.6 for MRK. Dividend yield: IRMD 0.94%, MRK 2.35%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IRMD$1.1B
MRK$357B
MRK is 329 times IRMD
Revenue, 12 months
IRMD$89M
MRK$67.4B
MRK is 754 times IRMD
Net income, 12 months
IRMD$24M
MRK$2.5B
MRK is 102 times IRMD
Operating margin
IRMD32.3%
MRK–
ROIC
IRMD22.3%
MRK3.9%
18.4 points apart
P/E
IRMD45.2
MRK145.6
MRK is 3.2 times IRMD
Dividend yield
IRMD0.9%
MRK2.4%
1.5 points apart
5-year return
IRMD+135.4%
MRK+101.1%
34.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IRMD+135.4%
MRK+101.1%
| Period | IRMDWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +2.0%Price +0.6% | +60.0%Price +55.5% |
| 3 years since November 16, 2023 | +110.2%+28.1% a yearPrice +100.3% | +55.2%+15.8% a yearPrice +41.6% |
| 5 years since November 15, 2021 | +135.4%+18.7% a yearPrice +113.6% | +101.1%+15.0% a yearPrice +72.6% |
| 10 years since November 17, 2016 | +731.1%+23.6% a yearPrice +654.1% | +227.6%+12.6% a yearPrice +141.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
IRMDiRadimedMRKMerck & Company
| Price | $84.84 | $144.46 |
|---|---|---|
| Market value | $1.1B | $357B |
| Enterprise value (EV) | $1.0B | $401B |
| P/E | 45.2 | 145.6 |
| P/E, 5-year median | 36.7 | 14.8 |
| P/B | 10.2 | 8.0 |
| EV/EBIT | 35.4 | 84.3 |
| Free cash flow yield | 2.4% | 4.1% |
| Revenue, 12 months | $89M | $67.4B |
|---|---|---|
| Net income, 12 months | $24M | $2.5B |
| Free cash flow, 12 months | $26M | $14.7B |
| Earnings per share, 12 months | $1.87 | $0.98 |
| Revenue growth, year on year | 14.4% | 1.3% |
| Revenue growth a year, past | +21.5%over 5 years | +9.4%over 5 years |
| EPS growth a year, past | +73.9%over 5 years | +21.2%over 5 years |
| Gross margin | 75.5% | 71.8% |
|---|---|---|
| Operating margin | 32.3% | – |
| Net margin | 26.9% | 3.6% |
| ROIC | 22.3% | 3.9% |
| ROE | 24.0% | 5.2% |
| Cash | $63M | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | 0.9% | 2.4% |
|---|---|---|
| Dividend per share, 12 months | $0.80 | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | 0.9% | 3.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($357B) is about 329.3 times iRadimed ($1.1B), at today's prices.
Since November 17, 2016, IRMD's price moved +654.1% and MRK's +141.5%. With dividends: IRMD +731.1% (+23.6% a year), MRK +227.6% (+12.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.94% for iRadimed and 2.35% for Merck & Company. Over the last twelve months they paid $0.80 and $3.40 per share.
At today's price, the P/E is 45.2 for IRMD and 145.6 for MRK. The median of the last five years was 36.7 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 26.9% for iRadimed and 3.6% for Merck & Company, and the operating margin 32.3% and –. Revenue was $89M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.